Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

PBYI

PUMA BIOTECHNOLOGY, INC.

Pharmaceutical Preparations · SIC 2834CIK 1401667Held by 2 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$228.0M
Net Income FY2025
$31.0M
EPS (Basic, as reported)
$0.62
Net Margin FY2025
13.6%
ROE FY2025
23.9%
Total Equity
$130.0M
Shares Out
52M
Business description

PUMA BIOTECHNOLOGY, INC. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2011–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 28 → 228 +30% CAGR
Revenue—28251272225253228236230228
Cost of revenue—(6)(35)(37)(39)(64)(55)(63)(64)(58)
Research & development(223)(208)(165)(133)(98)(72)————
Selling, general & administrative(54)(107)(146)(142)(118)(116)(90)(90)(80)(71)
General & administrative(54)—————————
Total operating expenses(277)(320)(346)(311)(256)(252)(204)(203)(200)(191)
Operating income(277)(292)(95)(39)(30)124333137
Interest expense—(1)(11)(15)(14)(13)(12)(13)(12)(7)
Interest & investment income1123001354
Other income (expense), net10(19)(36)(29)(30)(23)(10)(7)(2)
Pre-tax income——(114)(76)(60)(29)0232436
Income tax expense0000000(1)(6)(5)
Net income(276)(292)(114)(76)(60)(29)0223031
EPS — basic———($75595.00)($1.52)($0.72)$0.00$0.46$0.62$0.62
EPS — diluted————($1.52)($0.72)$0.00$0.45$0.62$0.61
Shares outstanding — basic (M)————404145474950
Shares outstanding — diluted (M)————404145484951

Showing the latest 10 of 15 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.